- Home
- WHLR vs XRTX Comparison
WHLR vs XRTX Comparison
Compare WHLR & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHLR | XRTX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.4M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | WHLR | XRTX |
|---|---|---|
| Price | $1.71 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 309.3K | 44.1K |
| Earning Date | 03-03-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 61.36 | N/A |
| Revenue | ★ $101,834,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.58 | $0.51 |
| 52 Week High | $6,719.86 | $1.79 |
Technical Indicators
Market Signals| Indicator | WHLR | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.80 |
| Support Level | N/A | $0.57 |
| Resistance Level | N/A | $0.60 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 57.69 |
Price Performance
Historical ComparisonAbout WHLR Wheeler Real Estate Investment Trust Inc.
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.